Immunization

Currently, there is no vaccine to prevent chlamydia, but treatment includes regimens of antibiotics, including doxycycline, azithromycin, and levofloxacin.

Lauren Angelo, PharmD, MBA, discussed current vaccination sentiments across the country and how misinformation has contributed to declining rates among US patients.

Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at Virginia Commonwealth University, discusses the current landscape of immunization recommendations.

Chichi Ilonzo Momah, PharmD, discussed what pharmacists can be doing to address vaccine hesitancy and the barriers impeding under-resourced communities.

COVID-19 vaccination before a SARS-CoV-2 infection was associated with a 75% reduced likelihood of long COVID symptoms that impact daily functioning among patients between the ages of 5 and 17 years.

IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.

Researchers investigated the acceptability of community pharmacy-led influenza vaccination and patients’ willingness to return for future immunization.

Pharmacy staff members said that VaxCheck was compatible with pharmacy workflow but there were several barriers to its implementation.

Measles is highly contagious, and the Texas Department of State Health Services said that additional cases are likely to occur in Gaines County, which had 57 cases as of February 21, 2025.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

In order to meet national targets, the United States should expand vaccination administration in complementary sites like pharmacies.

Among providers who took part in a recent study, 57% reported increased vaccination rates after implementing a quality improvement initiative.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

More detailed information can be found on the CDC’s website at www.cdc.gov/vaccines.

RBI-4000 is a self-replicating RNA (srRNA) vaccine developed to stimulate virus-neutralizing immune responses to rabies for prophylactic use.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

The US government is entrusting mRNA vaccine pioneers Moderna to develop protection for the gradually increasing threat of avian influenza.

A poll conducted by the Global Healthy Living Foundation found 11% of respondents with chronic conditions do not plan to get vaccinated for flu, COVID-19 or RSV.

Researchers compared the safety and reactogenicity of simultaneous doses of recombinant zoster vaccine paired with 2 separate types of inactivated influenza vaccines.

These recommendations were voted on at the October 2024 Advisory Committee on Immunization Practices meeting.

Patients who receive either Pfizer or GSK’s respiratory syncytial virus vaccine may be at increased risk of Guillain-Barré syndrome.

Researchers compared simultaneous and sequential administration of the mRNA COVID-19 and inactivated influenza vaccines.

Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.

Researchers aimed to identify the barriers impeding HPV vaccine uptake since 2019 among US mid-adults aged 27 to 45.